http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Vertex Pharma (VRTX) Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA
-
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference
-
Vertex to Participate in Upcoming September Investor Conferences
-
Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
-
Vertex Reports Second Quarter 2024 Financial Results
-
Vertex Pharma (VRTX) Announces FDA Acceptance of NDA for Suzetrigine
-
Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
-
10 policies if Trump wins and stock implications: Jefferies
-
Vertex Pharma (VRTX) Enters New Extension and Expansion of Drug Discovery Collaboration with Genomics
-
Orum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of Orum’s TPD²® Technology to Develop Novel Degrader-Antibody Conjugates
-
Vertex Pharma (VRTX) Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for CF
-
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
-
Vertex to Announce Second Quarter 2024 Financial Results on August 1
-
Vertex Pharma (VRTX) to Present Positive Results From Ongoing Phase 1/2 Study of VX-880
-
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
-
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
-
Vertex Pharma (VRTX) New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA
-
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
-
Vertex to Participate in Upcoming June Investor Conferences
-
Vertex Pharma (VRTX) Appoints Jennifer Schneider to its Board
-
Jennifer Schneider Elected to Vertex Board of Directors
-
Vertex Reports First Quarter 2024 Financial Results
-
Vertex Pharma (VRTX) Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
-
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
-
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
-
Vertex Pharma (VRTX) Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
-
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
-
Vertex (VRTX) Enters Into Agreement to Acquire Alpine Immune Sciences (ALPN)
-
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
-
Vertex to Announce First Quarter 2024 Financial Results on May 6
-
Vertex Pharma (VRTX) Advances Inaxaplin into Phase 3 Portion of Adaptive Phase 2/3 Trial
-
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
-
Vertex Pharma (VRTX) Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
-
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
-
Vertex Pharma (VRTX) Receives CHMP Positive Opinion for KALYDECO
-
Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older
-
Vertex to Participate in Upcoming Investor Conferences
-
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
-
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
-
Vertex Pharma (VRTX) Reports Positive Results From Trials of Vanzacaftor/Tezacaftor/Deutivacaftor
-
Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
-
Vertex Pharma (VRTX) Reports Positive Results From the VX-548 Phase 3 Program
-
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
-
Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
-
Vertex Pharma (VRTX) Announces US FDA Approval of CASGEVY for Treatment of Transfusion-Dependent Beta Thalassemia
-
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
-
Vertex Pharma (VRTX) Announces Approval of CASGEVY in Saudi Arabia
-
Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arab
-
Vertex Pharma (VRTX) Issues Pipeline and Business Updates
-
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
